• +1-646-491-9876
    • +91-20-67278686

    Search

    Multiple Sclerosis Pipeline Review H1 2017

    Multiple Sclerosis Pipeline Review H1 2017

    • Report Code ID: RW0001858675
    • Category Pharmaceuticals
    • No. of Pages 812
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Multiple Sclerosis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H1 2017, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

    Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 30, 32, 1, 168, 34 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 47 and 2 molecules, respectively.

    Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 9
    Multiple Sclerosis - Overview 10
    Multiple Sclerosis - Therapeutics Development 11
    Multiple Sclerosis - Therapeutics Assessment 48
    Multiple Sclerosis - Companies Involved in Therapeutics Development 70
    Multiple Sclerosis - Drug Profiles 160
    Multiple Sclerosis - Dormant Projects 746
    Multiple Sclerosis - Discontinued Products 763
    Multiple Sclerosis - Product Development Milestones 766
    Appendix 778

    List of Tables

    Number of Products under Development for Multiple Sclerosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..10) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..11) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..10) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..11) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..12) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..13) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..14) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..15) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..7) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Multiple Sclerosis - Pipeline by 2-BBB Medicines BV, H1 2017
    Multiple Sclerosis - Pipeline by 4D Pharma PLC, H1 2017
    Multiple Sclerosis - Pipeline by AB Science SA, H1 2017
    Multiple Sclerosis - Pipeline by AbbVie Inc, H1 2017
    Multiple Sclerosis - Pipeline by Abion Inc, H1 2017
    Multiple Sclerosis - Pipeline by Ablynx NV, H1 2017
    Multiple Sclerosis - Pipeline by Abzena Plc, H1 2017
    Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Actelion Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H1 2017
    Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2017
    Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H1 2017
    Multiple Sclerosis - Pipeline by Alkermes Plc, H1 2017
    Multiple Sclerosis - Pipeline by Allergan Plc, H1 2017
    Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H1 2017
    Multiple Sclerosis - Pipeline by Alvotech Iceland, H1 2017
    Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H1 2017
    Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H1 2017
    Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Aphios Corp, H1 2017
    Multiple Sclerosis - Pipeline by Apitope International NV, H1 2017
    Multiple Sclerosis - Pipeline by ARA Healthcare Pvt Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Argos Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
    Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Arven Ilac, H1 2017
    Multiple Sclerosis - Pipeline by Asterias Biotherapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by AstraZeneca Plc, H1 2017
    Multiple Sclerosis - Pipeline by Atara Biotherapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Athersys Inc, H1 2017
    Multiple Sclerosis - Pipeline by Atlantic Bio Sci LLC, H1 2017
    Multiple Sclerosis - Pipeline by Axxam SpA, H1 2017
    Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
    Multiple Sclerosis - Pipeline by BioApex sro, H1 2017
    Multiple Sclerosis - Pipeline by Biocad, H1 2017
    Multiple Sclerosis - Pipeline by Biocon Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Biogen Inc, H1 2017
    Multiple Sclerosis - Pipeline by BioHealthonomics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H1 2017
    Multiple Sclerosis - Pipeline by Bionovis SA, H1 2017
    Multiple Sclerosis - Pipeline by Bionure Farma SL, H1 2017
    Multiple Sclerosis - Pipeline by Biovista Inc, H1 2017
    Multiple Sclerosis - Pipeline by Bolder Biotechnology Inc, H1 2017
    Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Catalyst Pharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Celgene Corp, H1 2017
    Multiple Sclerosis - Pipeline by Cell Cure Neurosciences Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
    Multiple Sclerosis - Pipeline by Cinnagen Co, H1 2017
    Multiple Sclerosis - Pipeline by Cognosci Inc, H1 2017
    Multiple Sclerosis - Pipeline by Coherus BioSciences Inc, H1 2017
    Multiple Sclerosis - Pipeline by Commence Bio Inc, H1 2017
    Multiple Sclerosis - Pipeline by Compugen Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc, H1 2017
    Multiple Sclerosis - Pipeline by CuraVac Inc, H1 2017
    Multiple Sclerosis - Pipeline by Cyxone AB, H1 2017
    Multiple Sclerosis - Pipeline by DanDrit Biotech A/S, H1 2017
    Multiple Sclerosis - Pipeline by Denceptor Therapeutics Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Eisai Co Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Eli Lilly and Company, H1 2017
    Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H1 2017
    Multiple Sclerosis - Pipeline by Evotec AG, H1 2017
    Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Flex Pharma Inc, H1 2017
    Multiple Sclerosis - Pipeline by Forward Pharma A/S, H1 2017
    Multiple Sclerosis - Pipeline by FPRT Bio Inc, H1 2017
    Multiple Sclerosis - Pipeline by Gemac SA, H1 2017
    Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
    Multiple Sclerosis - Pipeline by GeNeuro SA, H1 2017
    Multiple Sclerosis - Pipeline by Genzyme Corp, H1 2017
    Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H1 2017
    Multiple Sclerosis - Pipeline by Glialogix Inc, H1 2017
    Multiple Sclerosis - Pipeline by Hansa Medical AB, H1 2017
    Multiple Sclerosis - Pipeline by Harbor Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Humabs BioMed SA, H1 2017
    Multiple Sclerosis - Pipeline by Hutchison China MediTech Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Immune Response BioPharma Inc, H1 2017
    Multiple Sclerosis - Pipeline by Immune Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Immungenetics AG, H1 2017
    Multiple Sclerosis - Pipeline by Immunwork Inc, H1 2017
    Multiple Sclerosis - Pipeline by Inception Sciences Inc, H1 2017
    Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Io Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Jyant Technologies Inc, H1 2017
    Multiple Sclerosis - Pipeline by Kadimastem Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Kadmon Corp LLC, H1 2017
    Multiple Sclerosis - Pipeline by KAHR medical Ltd, H1 2017
    Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Kancera AB, H1 2017
    Multiple Sclerosis - Pipeline by Karo Pharma AB, H1 2017
    Multiple Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
    Multiple Sclerosis - Pipeline by KPI Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2017
    Multiple Sclerosis - Pipeline by LFB SA, H1 2017
    Multiple Sclerosis - Pipeline by Lipocure Ltd, H1 2017
    Multiple Sclerosis - Pipeline by MacroGenics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Mapi Pharma Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Marathon Pharmaceuticals LLC, H1 2017
    Multiple Sclerosis - Pipeline by MedAnnex Ltd, H1 2017
    Multiple Sclerosis - Pipeline by MedDay SA, H1 2017
    Multiple Sclerosis - Pipeline by Medestea Research & Production SpA, H1 2017
    Multiple Sclerosis - Pipeline by MedImmune LLC, H1 2017
    Multiple Sclerosis - Pipeline by Merck KGaA, H1 2017
    Multiple Sclerosis - Pipeline by Meta-IQ ApS, H1 2017
    Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Mitotech SA, H1 2017
    Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
    Multiple Sclerosis - Pipeline by Mochida Pharmaceutical Co Ltd, H1 2017
    Multiple Sclerosis - Pipeline by MorphoSys AG, H1 2017
    Multiple Sclerosis - Pipeline by Mount Tam Biotechnologies Inc, H1 2017
    Multiple Sclerosis - Pipeline by Neuralstem Inc, H1 2017
    Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Neurofx Inc, H1 2017
    Multiple Sclerosis - Pipeline by Neuronax SAS, H1 2017
    Multiple Sclerosis - Pipeline by New World Laboratories Inc, H1 2017
    Multiple Sclerosis - Pipeline by Novartis AG, H1 2017
    Multiple Sclerosis - Pipeline by Nuevolution AB, H1 2017
    Multiple Sclerosis - Pipeline by Numab Innovation AG, H1 2017
    Multiple Sclerosis - Pipeline by Ogeda SA, H1 2017
    Multiple Sclerosis - Pipeline by Omeros Corp, H1 2017
    Multiple Sclerosis - Pipeline by OncoImmune Inc, H1 2017
    Multiple Sclerosis - Pipeline by Opexa Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Oryzon Genomics SA, H1 2017
    Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H1 2017
    Multiple Sclerosis - Pipeline by Pangen Biotech Inc., H1 2017
    Multiple Sclerosis - Pipeline by Parvus Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Pfenex Inc, H1 2017
    Multiple Sclerosis - Pipeline by Pfizer Inc, H1 2017
    Multiple Sclerosis - Pipeline by Pharmaxis Ltd, H1 2017
    Multiple Sclerosis - Pipeline by ProNoxis AB, H1 2017
    Multiple Sclerosis - Pipeline by Prothena Corp Plc, H1 2017
    Multiple Sclerosis - Pipeline by Quimatryx SL, H1 2017
    Multiple Sclerosis - Pipeline by ReceptoPharm Inc, H1 2017
    Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd, H1 2017
    Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Regenesance BV, H1 2017
    Multiple Sclerosis - Pipeline by Renovo Neural Inc, H1 2017
    Multiple Sclerosis - Pipeline by Resverlogix Corp, H1 2017
    Multiple Sclerosis - Pipeline by ReveraGen BioPharma Inc, H1 2017
    Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Rock Creek Pharmaceuticals Inc, H1 2017
    Multiple Sclerosis - Pipeline by Rodos BioTarget GmbH, H1 2017
    Multiple Sclerosis - Pipeline by SanBio Inc, H1 2017
    Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2017
    Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H1 2017
    Multiple Sclerosis - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Sorrento Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Spherium Biomed SL, H1 2017
    Multiple Sclerosis - Pipeline by Symic Biomedical Inc, H1 2017
    Multiple Sclerosis - Pipeline by Synthon Holdings BV, H1 2017
    Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H1 2017
    Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
    Multiple Sclerosis - Pipeline by TikoMed AB, H1 2017
    Multiple Sclerosis - Pipeline by Tiziana Life Sciences Plc, H1 2017
    Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2017
    Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H1 2017
    Multiple Sclerosis - Pipeline by TxCell SA, H1 2017
    Multiple Sclerosis - Pipeline by Vaccinex Inc, H1 2017
    Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H1 2017
    Multiple Sclerosis - Pipeline by Vicore Pharma AB, H1 2017
    Multiple Sclerosis - Pipeline by viDA Therapeutics Inc, H1 2017
    Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment Inc, H1 2017
    Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
    Multiple Sclerosis - Pipeline by Xenetic Biosciences Inc, H1 2017
    Multiple Sclerosis - Pipeline by XL-protein GmbH, H1 2017
    Multiple Sclerosis - Pipeline by Yungjin Pharm Co Ltd, H1 2017
    Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..7) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..8) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..9) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..10) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..11) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..12) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..13) , H1 2017
    Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..14) , H1 2017
    Multiple Sclerosis - Discontinued Products, H1 2017
    Multiple Sclerosis - Discontinued Products, H1 2017 (Contd..1) , H1 2017
    Multiple Sclerosis - Discontinued Products, H1 2017 (Contd..2) , H1 2017

    List of Figures

    Number of Products under Development for Multiple Sclerosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    2-BBB Medicines BV
    4D Pharma PLC
    AB Science SA
    AbbVie Inc
    Abion Inc
    Ablynx NV
    Abzena Plc
    Acorda Therapeutics Inc
    Actelion Ltd
    Adamas Pharmaceuticals Inc
    Addex Therapeutics Ltd
    Adhaere Pharmaceuticals Inc
    Aegis Therapeutics LLC
    Affectis Pharmaceuticals AG
    AiCuris GmbH & Co KG
    Alkermes Plc
    Allergan Plc
    Alpha Cancer Technologies Inc
    Alvotech Iceland
    Amarna Therapeutics BV
    Anavex Life Sciences Corp
    Antisense Therapeutics Ltd
    Aphios Corp
    Apitope International NV
    ARA Healthcare Pvt Ltd
    Argos Therapeutics Inc
    Arrien Pharmaceuticals LLC
    Artielle ImmunoTherapeutics Inc
    Arven Ilac
    Asterias Biotherapeutics Inc
    AstraZeneca Plc
    Atara Biotherapeutics Inc
    Athersys Inc
    Atlantic Bio Sci LLC
    Axxam SpA
    Bio-Cancer Treatment International Ltd
    BioApex sro
    Biocad
    Biocon Ltd
    Biogen Inc
    BioHealthonomics Inc
    Biomar Microbial Technologies
    Bionovis SA
    Bionure Farma SL
    Biovista Inc
    Bolder Biotechnology Inc
    BrainStorm Cell Therapeutics Inc
    Bristol-Myers Squibb Company
    CASI Pharmaceuticals Inc
    Catalyst Pharmaceuticals Inc
    Celgene Corp
    Cell Cure Neurosciences Ltd
    Cell2B Advanced Therapeutics SA
    Cinnagen Co
    Cognosci Inc
    Coherus BioSciences Inc
    Commence Bio Inc
    Compugen Ltd
    Connexios Life Sciences Pvt Ltd
    Critical Outcome Technologies Inc
    CuraVac Inc
    Cyxone AB
    DanDrit Biotech A/S
    Denceptor Therapeutics Ltd
    Dimerix Bioscience Pty Ltd
    Eisai Co Ltd
    Eli Lilly and Company
    Evgen Pharma Plc
    Evotec AG
    F. Hoffmann-La Roche Ltd
    Flex Pharma Inc
    Forward Pharma A/S
    FPRT Bio Inc
    Gemac SA
    Genervon Biopharmaceuticals LLC
    GeNeuro SA
    Genzyme Corp
    GlaxoSmithKline Plc
    Glialogix Inc
    Hansa Medical AB
    Harbor Therapeutics Inc
    Humabs BioMed SA
    Hutchison China MediTech Ltd
    Immune Response BioPharma Inc
    Immune Therapeutics Inc
    Immungenetics AG
    Immunwork Inc
    Inception Sciences Inc
    Innate Immunotherapeutics Ltd
    Inovio Pharmaceuticals Inc
    Io Therapeutics Inc
    Jyant Technologies Inc
    Kadimastem Ltd
    Kadmon Corp LLC
    KAHR medical Ltd
    KaloBios Pharmaceuticals Inc
    Kancera AB
    Karo Pharma AB
    Karyopharm Therapeutics Inc
    Kissei Pharmaceutical Co Ltd
    KPI Therapeutics Inc
    Kyorin Pharmaceutical Co Ltd
    Lead Discovery Center GmbH
    LFB SA
    Lipocure Ltd
    MacroGenics Inc
    Mapi Pharma Ltd
    Marathon Pharmaceuticals LLC
    MedAnnex Ltd
    MedDay SA
    Medestea Research & Production SpA
    MedImmune LLC
    Merck KGaA
    Meta-IQ ApS
    Mitochon Pharmaceuticals Inc
    Mitotech SA
    Mitsubishi Tanabe Pharma Corp
    Mochida Pharmaceutical Co Ltd
    MorphoSys AG
    Mount Tam Biotechnologies Inc
    Neuralstem Inc
    Neuren Pharmaceuticals Ltd
    Neurofx Inc
    Neuronax SAS
    New World Laboratories Inc
    Novartis AG
    Nuevolution AB
    Numab Innovation AG
    Ogeda SA
    Omeros Corp
    OncoImmune Inc
    Opexa Therapeutics Inc
    Oryzon Genomics SA
    OSE Immunotherapeutics
    Pangen Biotech Inc.
    Parvus Therapeutics Inc
    Pfenex Inc
    Pfizer Inc
    Pharmaxis Ltd
    ProNoxis AB
    Prothena Corp Plc
    Quimatryx SL
    ReceptoPharm Inc
    RedHill Biopharma Ltd
    RegeneRx Biopharmaceuticals Inc
    Regenesance BV
    Renovo Neural Inc
    Resverlogix Corp
    ReveraGen BioPharma Inc
    Rigel Pharmaceuticals Inc
    Rock Creek Pharmaceuticals Inc
    Rodos BioTarget GmbH
    SanBio Inc
    Santhera Pharmaceuticals Holding AG
    Sareum Holdings Plc
    Senju Pharmaceutical Co Ltd
    Sorrento Therapeutics Inc
    Spherium Biomed SL
    Symic Biomedical Inc
    Synthon Holdings BV
    Teikoku Pharma USA Inc
    Teva Pharmaceutical Industries Ltd
    TikoMed AB
    Tiziana Life Sciences Plc
    Toleranzia AB
    Topas Therapeutics GmbH
    TxCell SA
    Vaccinex Inc
    Vakzine Projekt Management GmbH
    Vicore Pharma AB
    viDA Therapeutics Inc
    Virogenomics BioDevelopment Inc
    VivaCell Biotechnology Espana SL
    Xenetic Biosciences Inc
    XL-protein GmbH
    Yungjin Pharm Co Ltd
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//multiple-sclerosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//multiple-sclerosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//multiple-sclerosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments